Bank of America spends more than $250 million on GLP-1s

Bank of America spends over $250 million annually on GLP-1 weight-loss drugs for its 210,000 employees, as CEO Brian Moynihan describes it as a worthwhile long-term investment in employee health. The bank's $2 billion annual healthcare budget includes initiatives to reduce costs for the medication, which is causing challenges for some employers and employees due to coverage and affordability issues.